Literature DB >> 26334083

Prostate cancer: No evidence for adjuvant chemotherapy in high-risk disease.

Peter Albers1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26334083     DOI： 10.1038/nrurol.2015.219

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  8 in total

1.  Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911).

Authors:  Michel Bolla; Hein van Poppel; Bertrand Tombal; Kris Vekemans; Luigi Da Pozzo; Theo M de Reijke; Antony Verbaeys; Jean-François Bosset; Roland van Velthoven; Marc Colombel; Cees van de Beek; Paul Verhagen; Alphonsus van den Bergh; Cora Sternberg; Thomas Gasser; Geertjan van Tienhoven; Pierre Scalliet; Karin Haustermans; Laurence Collette
Journal:  Lancet       Date:  2012-10-19       Impact factor: 79.321

2.  Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31.

Authors:  Colleen A Lawton; Kathryn Winter; David Grignon; Miljenko V Pilepich
Journal:  J Clin Oncol       Date:  2005-02-01       Impact factor: 44.544

3.  A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902.

Authors:  Seth A Rosenthal; Daniel Hunt; A Oliver Sartor; Kenneth J Pienta; Leonard Gomella; David Grignon; Raghu Rajan; Kevin J Kerlin; Christopher U Jones; Michael Dobelbower; William U Shipley; Kenneth Zeitzer; Daniel A Hamstra; Viroon Donavanik; Marvin Rotman; Alan C Hartford; Jeffrey Michalski; Michael Seider; Harold Kim; Deborah A Kuban; Jennifer Moughan; Howard Sandler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-07-21       Impact factor: 7.038

4.  Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?

Authors:  I F Tannock
Journal:  J Clin Oncol       Date:  1985-07       Impact factor: 44.544

5.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Authors:  Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

6.  Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.

Authors:  Seth A Rosenthal; Kyoungwha Bae; Kenneth J Pienta; Mark L Sobczak; Sucha O Asbell; Raghu Rajan; Kevin J Kerlin; Jeff M Michalski; Howard M Sandler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-11-05       Impact factor: 7.038

7.  Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.

Authors:  Anthony V D'Amico; Judd Moul; Peter R Carroll; Leon Sun; Deborah Lubeck; Ming-Hui Chen
Journal:  J Clin Oncol       Date:  2003-06-01       Impact factor: 44.544

8.  Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer.

Authors:  P C Albertsen; J A Hanley; D F Gleason; M J Barry
Journal:  JAMA       Date:  1998-09-16       Impact factor: 56.272
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.